5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compa...( BRIDGEWATER N.J. July 6 /- Sano.....),Health

BRIDGEWATER, N.J., July 6 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the results of the long-term, 5-year study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopathy in patients with type 2 diabetes, published on-line in Diabetologia (DOI 10.1007/s00125-009-1415-7) showed similar effects on retinopathy and overall safety in the two treatment groups. This is the longest controlled study ever reported using insulin glargine.

Diabetic retinopathy is a major cause of blindness in patients with diabetes. It is a progressive disease that results from cellular proliferation within the eye. The stimulation of IGF1 receptors is involved in this process. In the study of patients with retinopathy, the progression of diabetic retinopathy was similar in the two treatment groups over the long-term course of treatment.

This indicates that Lantus does not have mitogenic effects different from the human NPH insulin within the eye.

"This 5-year study is the longest randomized controlled study with insulin glargine versus NPH human insulin," said lead investigator Julio Rosenstock, MD, Director of the Dallas Diabetes and Endocrine Center at Medical City and also Clinical Professor of Medicine, University of Texas Southwestern Medical School. "This study demonstrated no evidence of a greater risk of progression of retinopathy with insulin glargine."

The 5-year open-label study was specifically designed to further characterize the retinal safety profile of Lantus(R) versus NPH in 1024 patients (Lantus(R) once daily: 515 patients; NPH twice daily: 509 patients). Retinopathy progression was assessed using serial fundus photography.
'/>"/>